Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim D-W, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. Haematologica 2024;109(10):3251-3260; https://doi.org/10.3324/haematol.2023.283428.